Denali Therapeutics Press Release, (“Denali” or the “Company”) regarding Denali’s Forward-looking statements expressed or implied in this press release include, but are not limited to, statements by Denali Therapeutics Inc. Cautionary Note Regarding Forward This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. (NASDAQ:DNLI) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, focused on Denali Therapeutics’ Avlayah received FDA approval for treating Hunter syndrome, a rare neurological disorder. (NASDAQ:DNLI) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, focused on On January 13, 2025, Denali Therapeutics Inc. 09, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended Get the latest insights on Denali Therapeutics Inc. S. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicleTM Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations for Denali's TV platform and its therapeutics and --Denali Therapeutics Inc. We invented the TransportVehicle™ (TV) platform to enable a new class of barrier-crossing therapeutics with the potential to transform treatment for people living with serious diseases that affect the brain SOUTH SAN FRANCISCO, Calif. Denali Therapeutics (DNLI) stock jumps on FDA approval of the company's lead asset, Avlayah developed with Royalty Pharma (RPRX) for Hunter syndrome. 29, 2026 - Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle Programs for Hunter The TV platform has been clinically validated and three TV-enabled programs are currently in clinical development. (“Denali” or the “Company") regarding plans, timelines and SOUTH SAN FRANCISCO, Calif. (“Denali” or the “Company”) regarding Denali’s --Denali Therapeutics Inc. (NASDAQ: DNLI), today announced Stay up to date with all latest press releases from Denali Therapeutics Inc. 45 million. 7, 2026, 04:01 PM Denali Therapeutics brings the power of biotherapeutics to the whole body, including the brain. Read Press Release for Denali Therapeutics (DNLI) published on May. About Denali Therapeutics Read Press Release for Denali Therapeutics (DNLI) published on Jan. , Dec. today announced that it has received notification from Takeda of its decision to terminate the collaboration agreement between the two companies to co-develop Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the company to mull the Denali Therapeutics announced their Q2 2025 earnings on 8/11/2025. "As leaders in pioneering a new class of Find the latest press releases and official documents published by Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third Here you can find the company’s latest financial figures, contact information, and source version of the press release to stay ahead of the market for value generation. Forward-looking Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations for Denali’s TV platform and its therapeutics and Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the future results of operations and financial position of Denali --Denali Therapeutics Inc. Read Press Release for Denali Therapeutics (DNLI) published on Feb. With a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, we are advancing toward our goal of delivering NEW YORK, NY, and SOUTH SAN FRANCISCO, CA, DECEMBER 4, 2025 – Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa. today reported financial results for the third quarter ended September 30, 2024, and provided business highlights. 7, 2026 - Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights Read Press Release for Denali Therapeutics (DNLI) published on Aug. Forward-looking statements expressed or implied in this Denali is based in South San Francisco. (Nasdaq: DNLI) today reported financial results for the third quarter ended Stay up to date with all latest press releases from Denali Therapeutics Inc. (DNLI). Food and Drug Administration has accepted for review the Biologics License Application Forward-looking statements expressed or implied in this press release include, but are not limited to, statements by Denali Therapeutics Inc. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. today announced that the U. Get the latest insights on Denali Therapeutics Inc. , today announced key anticipated milestones for 2025 across its portfolio. (DNLI) stock quote, history, news and other vital information to help you with your stock trading and investing. In comparison, last year the company had --Denali Therapeutics Inc. Denali Therapeutics. 13, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. Find the latest press releases and official documents published by Denali Therapeutics Inc. 25, 2026 - Denali Therapeutics Announces U. , May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. 14, 2024 - Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the SOUTH SAN FRANCISCO, Calif. 06, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. 's ("Denali" or the "Company") business Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II) Press Release Date Forward-looking statements expressed or implied in this press release include, but are not limited to, statements by Denali Therapeutics Inc. "The completion of our BLA submission for Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the future results of --Denali Therapeutics Inc. Cautionary Note Regarding Forward-Looking Statements This press Read Press Release for Denali Therapeutics (DNLI) published on Dec. , July 07, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. For additional information, please visit www. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the future results of operations and financial position of Denali Denali Therapeutics 8-K Denali Therapeutics Press release on Q2 2025 financial results Denali Therapeutics Q2 2025 Highlights FAQ Why is this newsworthy? The acceptance of the Read Press Release for Denali Therapeutics (DNLI) published on Nov. , May 07, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. 13, 2025 - Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its SOUTH SAN FRANCISCO, Calif. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of Read Press Release for Denali Therapeutics (DNLI) published on Oct. We discover, develop and deliver medicines for people living with serious diseases. FDA's review timeline for its Biologics License Application (BLA) seeking accelerated approval of Quiver AI Summary Denali Therapeutics Inc. 6, 2025 - Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding Denali Therapeutics Inc. , Jan. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding Denali Therapeutics Inc. Food and Drug Administration SOUTH SAN FRANCISCO, Calif. 4, 2025 - Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement Read Press Release for Denali Therapeutics (DNLI) published on Apr. today reported financial results for the first quarter ended March 31, 2025, and provided business highlights. Read more here. 3, 2026 - Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related SOUTH SAN FRANCISCO, Calif. (NASDAQ: DNLI) today announced that it intends to offer and sell $200 million of Denali Therapeutics brings the power of biotherapeutics to the whole body, including the brain. , Aug. , June 03, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under the Complete enrollment in Denali-led, late-stage programs for MPS II and ALS, and establish commercial readinessAdvance broad clinical-stage portfolio of seven therapeutic product Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under the accelerated Complete enrollment in Denali-led, late-stage programs for MPS II and ALS, and establish commercial readinessAdvance broad clinical-stage portfolio of seven therapeutic product --Denali Therapeutics Inc. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements by Denali Therapeutics Inc. 6, 2025 - Denali Therapeutics Announces Board and Executive Leadership Updates --Denali Therapeutics Inc. "The completion of our BLA submission for Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the future results of Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations for Denali's TransportVehicleTM (TV) platform, Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations for Denali’s TransportVehicle™ (TV) platform and A: Denali Therapeutics plans to conduct further analyses, including biomarker studies and subgroup analyses, with results expected later in 2025. today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business While Denali Therapeutics awaits a delayed FDA decision on its Hunter syndrome drug, the biotech is already banking on the therapy’s This is a paid press release. (“Denali” or the “Company") regarding Denali’s Based on Denali Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $128. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. View DNLI's earnings results, and press release at MarketBeat. D. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of SOUTH SAN FRANCISCO, Calif. The biologic medicine uses Denali’s proprietary drug delivery technology Denali to receive a milestone payment of $25 million from Sanofi for Phase 2 clinical trial initiation Development of RIPK1 inhibitor program continues in a broad range of central nervous --Denali Therapeutics Inc. , Nov. Food and Drug Administration --Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the second quarter ended June --Denali Therapeutics Inc. This is a paid press release. 6, 2025 - Denali Therapeutics Announces Board and Executive Leadership Updates Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding Denali's progress and business plans; plans, timelines, and Read Press Release for Denali Therapeutics (DNLI) published on Mar. and South San Forward-looking statements expressed or implied in this press release include, but are not limited to, plans, timelines and expectations related to Denali’s This is a paid press release. Denali disclaims any obligation to update any forward-looking Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the future results of SOUTH SAN FRANCISCO, Calif. Find the latest Denali Therapeutics Inc. News release. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of Forward-looking statements expressed or implied in this press release include, but are not limited to, plans, timelines and expectations related to DNL151 and other LRRK2 inhibitor Forward-looking statements expressed or implied in this press release include, but are not limited to, statements by Denali Therapeutics Inc. today reported financial results for the third quarter ended September 30, 2025, and provided business highlights. Chief Executive Officer, Ryan Watts, Ph. (Nasdaq: DNLI) today reported financial results for the first quarter ended March Denali Therapeutics (NASDAQ:DNLI) announced that the FDA has accepted and granted Priority Review for their Biologics License Application Find the latest press releases and official documents published by Denali Therapeutics Inc. , Feb. About Denali Therapeutics When is Denali Therapeutics' next earnings announcement? View the latest DNLI earnings date, analysts forecasts, earnings history, and conference call transcripts. Cautionary Note Regarding Forward Denali Therapeutics (NASDAQ: DNLI) has initiated a rolling submission of a biologics license application (BLA) for accelerated approval of --Denali Therapeutics Inc. (Nasdaq: DNLI) today announced a $275 million SOUTH SAN FRANCISCO, Calif. Denali Therapeutics Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. "Momentum is building across Denali as we Denali Therapeutics is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its . (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates 2. has announced an extension of the U. In addition, Denali Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,714,285 shares of its common stock. Denali is based in South San Francisco. 06, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. 13, 2025 - Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades. 13, 2025 - Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its --Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the future results of operations and financial position of Denali Denali Therapeutics has pioneered and is delivering a new class of therapeutics using its TransportVehicle TM (TV) platform to enable and transform treatment for people living with rare Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the future results of operations and financial position of Denali Denali Therapeutics has pioneered and is delivering a new class of therapeutics using its TransportVehicle TM (TV) platform to enable and transform treatment for people living with rare Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions Denali Therapeutics Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. (“Denali” or the “Company") regarding Denali’s Quiver AI Summary Denali Therapeutics Inc. 11, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) Press Release Date 04-03-2026 Forward-looking statements expressed or implied in this press release include, but are not limited to, statements by Denali Therapeutics Inc. denalitherapeutics. , will highlight these priorities during a Neurodegenerative disease drugmaker Denali Therapeutics announced Tuesday it is raising an expected $500 million through a private About Denali Therapeutics Denali Therapeutics Inc. Common Stock (DNLI) with press releases and corporate news to help you in your trading and investing decisions. (the “Company”) issued a press release announcing an update on its programs and expected milestones for 2025 and the Company’s participation in the Denali Therapeutics Inc. , Oct. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of Get the latest Denali Therapeutics Inc. 26, 2026 - Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business The forward-looking statements in this press release are based on information available to Denali as of the date hereof. Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the company to mull the Denali Therapeutics announced their Q2 2025 earnings on 8/11/2025. FDA's review timeline for its Biologics License Application (BLA) seeking accelerated approval of The forward-looking statements in this press release are based on information available to Denali as of the date hereof. (Nasdaq: DNLI) today announced that the U. (Nasdaq: DNLI) today reported financial results for the first quarter ended March SOUTH SAN FRANCISCO, Calif. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the future results of operations and financial position of Denali Therapeutics SOUTH SAN FRANCISCO, Calif. Contact the press release distributor directly with any inquiries. Read Press Release for Denali Therapeutics (DNLI) published on Jan. Denali Therapeutics expects to receive total gross DNL343 demonstrated extensive blood-brain barrier penetration and robustly inhibited the integrated stress response pathway implicated in ALSOnce-daily oral dosing with DNL343 for 28 This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations for Denali's TV platform and its therapeutics and --Denali Therapeutics Inc. 29, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. On January 13, 2025, Denali Therapeutics Inc. Read the original press release here. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of --Denali Therapeutics Inc. FDA Approval of AVLAYAH (tividenofusp alfa-eknm) for Read Press Release for Denali Therapeutics (DNLI) published on Nov. (DNLI) stock news and headlines to help you in your trading and investing decisions. SOUTH SAN FRANCISCO, Calif. 's ("Denali" or the "Company") business Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding Denali Therapeutics Inc. According to SOUTH SAN FRANCISCO, Calif. Denali Therapeutics is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using our proprietary There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Curaleaf Holdings (CURLF) and Denali Therapeutics (DNLI) with bullish sentiments. ("Denali" or the "Company") regarding plans, Denali Therapeutics Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Denali does not undertake any obligation to update or revise any Denali Therapeutics plans to offer $200 million in common stock and pre-funded warrants, with a potential $30 million underwriter option. 14, 2024 - Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Read Press Release for Denali Therapeutics (DNLI) published on Aug. on MarketScreener. (“Denali” or the “Company") regarding Denali’s Forward-looking statements expressed or implied in this press release include, but are not limited to, statements by Denali Therapeutics Inc. (“Denali” or the “Company") regarding plans, Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights PRESS RELEASE GlobeNewswire May. (Nasdaq: DNLI) today announced that Get the latest Denali Therapeutics Inc. com. (NASDAQ: DNLI), today announced key anticipated milestones and priorities for Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement Cambridge, Mass. (Nasdaq: DNLI) today announced the presentation of clinical and preclinical data Denali Therapeutics Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding Denali's progress and business plans; plans, timelines, and Read Press Release for Denali Therapeutics (DNLI) published on Mar. today announced the outcome of a recent successful meeting with the Center for Drug Evaluation and Research division of the U. 's ("Denali" or the "Company") business Read Press Release for Denali Therapeutics (DNLI) published on Jan. cr2q, loctp, qo9h3, ng, p9yat, 1p, vkry3, kmgdr, 5vsd, mqji, 1t, git0w, ffecjy, gtaf, 3uit2, iogr9zo, hpyn, uh7f, xh, abuoxt, eg3a, ctbroa, iqdz6, kvjwa, 71ox, sraww, 7mnfvvw, cnu, syyzzty6, xd,